As of May 22
| +0.11 / +1.64%|
The 1 analysts offering 12-month price forecasts for Oramed Pharmaceuticals Inc have a median target of 30.00, with a high estimate of 30.00 and a low estimate of 30.00. The median estimate represents a +339.88% increase from the last price of 6.82.
The current consensus among 1 polled investment analysts is to Buy stock in Oramed Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.